Cannara Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023
For the nine months, sales was CAD 2.66 million compared to CAD 2.55 million a year ago. Revenue was CAD 39.28 million compared to CAD 24.05 million a year ago. Net income was CAD 2.31 million compared to net loss of CAD 0.248025 million a year ago. Basic earnings per share from continuing operations was CAD 0.03 compared to basic loss per share from continuing operations of CAD 0.01 a year ago. Diluted earnings per share from continuing operations was CAD 0.03 compared to diluted loss per share from continuing operations of CAD 0.01 a year ago.